📰 Timothya Springer News
Timothya Springer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Timothya Springer. Real-time updates on events, politics, business and more.
May 27, 2024
HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]
May 27, 2024
HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]
May 26, 2024
HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy […]
May 26, 2024
HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics […]
May 15, 2024
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Stock analysts at Leerink Partnrs boosted their Q2 2024 earnings estimates for Cartesian Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.95) per share for the quarter, up from their prior […]
April 27, 2024
Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings at ($1.09) […]
April 26, 2024
Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings at […]
April 26, 2024
Cartesian Therapeutics (NASDAQ:RNAC – Free Report) had its price target upped by HC Wainwright from $2.00 to $54.00 in a research report released on Tuesday, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($0.27) EPS, Q2 2024 earnings at […]
April 26, 2024
Leerink Partnrs reissued their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings […]
April 20, 2024
For the third year in a row, we’re celebrating the companies that do business better—with passion, purpose and a people-first outlook